Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

NCT00636740 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone-Refractory Prostate Cancer

Interventions

DRUG: Zoledronic Acid 20mg Tablets
DRUG: Zoledronic Acid
DRUG: Zoledronic Acid 20mg Tablets

Sponsor

Merrion Pharmaceuticals, LLC